Table 7.
Cardiovascular activity of Milrinone in instrumented anesthetized normal rats.
| Parameters | Normal | ||
|---|---|---|---|
| Baseline | Milrinone | % Δ from baseline | |
| HR (bpm) | 353 ± 9 | 376 ± 15* | 6 ± 2 |
| MAP (mmHg) | 118 ± 4 | 79 ± 5* | −33 ± 3 |
| LV—ESP (mmHg) | 121 ± 3 | 77 ± 6* | −36 ± 4 |
| LV—EDP (mmHg) | 5.4 ± 0.5 | 3.4 ± 0.7* | −42 ± 8 |
| LV—EDV (RVU) | 17.6 ± 1.1 | 16.4 ± 1.0* | −7 ± 1 |
| SW (mmHg * RVU * 103) | 1.9 ± 0.3 | 1.5 ± 0.3* | −20 ± 8 |
| PVA (mmHg * RVU * 103) | 2.3 ± 0.3 | 1.6 ± 0.3* | −32 ± 9 |
| ESPVR (mmHg/RVU) | 23.8 ± 1.8 | 35.0 ± 3.7* | 45 ± 9 |
| PRSW (mmHg) | 45 ± 4 | 63 ± 6* | 41 ± 9 |
| EDPVR (mmHg/RVU) | 1.8 ± 0.3 | 1.4 ± 0.3* | −19 ± 8 |
| LV—Tau (ms) | 8.5 ± 0.4 | 6.3 ± 0.3* | −25 ± 4 |
Changes in systemic and LV hemodynamics indices, and LV mechanical and energetic parameters were measured at baseline, and following at least 30 min of continuous IV infusion of Milrinone (10 μg/kg/min, n = 12). Summary data as values are mean ± standard error of the mean and % change from baseline.
*
P < 0.05 vs. baseline.